Table 1.
Clinical trials of CAR-T cells in China.
| Target antigen | Diseases | CAR | Gene-editing | NCT number |
|---|---|---|---|---|
| CD19 | ALL | NA | LV CRISPR-Cas9 | NCT03229876 |
| CD19 | B-cell lymphoma B-cell ALL |
CD28-CD3ζ | LV | NCT03559439 |
| CD19 | ALL B-cell lymphoma |
NA | LV | NCT03366350 |
| CD19 | ALL B-cell lymphoma |
NA | LV | NCT03366324 |
| CD19 | ALL | NA | NA | NCT03544021 |
| CD19 | Acute leukemia | NA | NA | NCT03232619 |
| CD19 | Lymphoma | NA | NA | NCT03488160 |
| CD19 | B-cell ALL | NA | LV | NCT03263208 |
| CD19 | B-cell ALL B-cell lymphoma |
4-1BB-CD3ζ | LV | NCT03281551 |
| CD19 | Hematological malignancies | NA | NA | NCT03344705 |
| CD19 | Relapsed NHL | NA | NA | NCT03540303 |
| CD19 | Relapsed/refractory ALL | NA | NA | NCT03423706 |
| CD19 | NHL | NA | NA | NCT03355859 |
| CD19 | NHL | NA | NA | NCT03344367 |
| CD19 | Leukemia Lymphoma |
NA | NA | NCT02546739 |
| CD19 | Refractory/relapsed NHL | NA | LV | NCT03299738 |
| CD19 | NHL | CD28-CD3ζ | NA | NCT03497533 |
| CD19 | ALL | NA | NA | NCT03327285 |
| CD19 and CD22 | Lymphoma | NA | NA | NCT03468153 |
| CD19 and CD20/CD22 | B-cell leukemia B-cell lymphoma |
NA | CRISPR-Cas9 | NCT03398967 |
| CD19 or CD19 and CD22 | B-cell leukemia | NA | NA | NCT03463928 |
| CD19/BCMA | MM | NA | NA | NCT03455972 |
| CD19 and CD22 | B-cell leukemia B-cell lymphoma |
NA | NA | NCT03098355 |
| CD19/BCMA/GPC3/GLD18 | B-cell lymphoma B-cell leukemia Myeloma Hepatocellular carcinoma Pancreatic carcinoma Adenocarcinoma of esophagogastric Junction |
NA | LV | NCT03302403 |
| CD19/Mesothelin | Pancreatic cancer | 4-1BB-CD3ζ | LV | NCT03497819 |
| CD19/CD20/CD22/CD10/CD33/CD38/CD56/CD117/CD123/CD34/MUC1 | ALL AML Myelodysplastic syndromes |
NA | NA | NCT03291444 |
| CD133/GD2/MUC1/CD117 or other marker positive sarcoma | Osteoid sarcoma Ewing sarcoma |
NA | NA | NCT03356782 |
| EpCAM | Gastrointestinal neoplasms | NA | NA | NCT03563326 |
| BCMA/CD138/CD38/CD56 | Relapsed/refractory MM | NA | NA | NCT03473496 |
| CD38/CD33/CD56/CD123/CD117/CD133/CD34/MUC1 | Relapsed/refractory AML | NA | NA | NCT03473457 |
| GD2/PSMA/MUC1/Mesothelin | Cervical cancer | NA | NA | NCT03356795 |
| CD22/CD30/BCMA/CLL-1 | Leukemia Lymphoma MM |
NA | LV | NCT03312205 |
| AFP | Hepatocellular carcinoma | CD28-CD3ζ | LV | NCT03349255 |
| CD123 | AML | NA | NA | NCT03556982 |
| CD4 | HIV/AIDS | CD28-CD3ζ | RV | NCT03240328 |
| CD20 | Relapsed/refractory B-cell lymphomas | NA | NA | NCT03576807 |
| EGFR | Metastatic colorectal cancer | 4-1BB-CD28-CD3ζ | NA | NCT03542799 |
| BCMA | MM | NA | NA | NCT03322735 |
| CD22 | Leukemia Lymphoma |
NA | NA | NCT03262298 |
| IM19 | NHL | 4-1BB-CD3ζ/CD28-CD3ζ | NA | NCT03528421 |
| Mesothelin | Solid tumor | NA | CRISPR-Cas9 | NCT03545815 |
| MUC1 | Lung neoplasm malignant | NA | NA | NCT03525782 |
| CCT301-38/CCT301-59 | Renal cell carcinoma | NA | NA | NCT03393936 |
| BCMA | Refractory or relapsed MM | CD28-CD3ζ | LV | NCT03380039 |
| EGFRVIII/IL13Rα2/Her-2/EphA2/CD133/GD2 | Glioma | NA | LV | NCT03423992 |
| MUC1/GD2/MAGE-A1/MAGE-A4/Mesothelin | Lung cancer | NA | LV | NCT03356808 |
CAR: chimeric antigen receptor; NCT: national clinical trial; CD: cluster of differentiation; ALL: acute lymphoblastic leukemia; LV: lentiviral; CRISPR: clustered regularly interspaced short palindromic repeats; NHL: non-Hodgkin lymphoma; BCMA: B cell maturation antigen; MM: multiple myeloma; GPC3: glypican 3; AML: acute myelocytic leukemia; CLL: chronic lymphocytic leukemia; AFP: alpha fetoprotein; MUC1: Mucin-1; GD2: disialoganglioside; EpCAM: epithelial cell adhesion molecule; PSMA: prostate-specific membrane antigen; HIV: human immunodeficiency virus; AIDS: acquired immune deficiency syndrome; RV: retroviral; EGFR: epidermal growth factor receptor; IL: interlukin; Her-2: human epidermal growth factor receptor 2; EphA2: ephrin type-A receptor 2; MAGE: melanoma-associated antigen; NA: not available.